Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Last Updated: 2026

Revolution Medicines

Rank#585

Market Cap43.24B

CountryUnited States

Summary

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

History

Revolution Medicines was founded in 2016. It engaged in a global collaboration agreement with Genentech, a member of the Roche Group, and was granted more than $125 million in funding.

Mission

Revolution Medicines is dedicated to transforming the treatment of cancer and chronic viral diseases by targeting critical regulatory pathways.

Vision

Revolution Medicines’ vision is to realise the promise of precision medicine by discovering and developing precision oncology and curative treatments for cancers and other serious diseases.

References

https://in.investing.com/equities/revolution-medicines-inc

https://finance.yahoo.com/quote/RVMD/profile?p=RVMD

https://www.crunchbase.com/organization/revolution-medicines

https://sec.report/CIK/0001628171

https://companiesmarketcap.com/

https://www.revmed.com

Leadership team

Dr. Mark A. Goldsmith Ph.D. (CEO, Pres & Chairman)

Mr. Jack Anders (Chief Financial Officer)

Ms. Margaret A. Horn J.D. (Chief Operating Officer)

Products / Services

Health Care, Life Science, Medical

Number of Employees

100 - 500

Address

Redwood City, California, United States

Established

2015-01-01

Company Registration

SEC CIK number: 0001628171

Revenue

20M - 100M

Traded as

RVMD

Website

https://www.revmed.com

Social Media

Last Updated: 2026

Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Learn More

Last Updated: 2026

Revolution Medicines

Rank#585

Market Cap43.24B

CountryUnited States

Summary

History

Revolution Medicines was founded in 2016. It engaged in a global collaboration agreement with Genentech, a member of the Roche Group, and was granted more than $125 million in funding.

Mission

Revolution Medicines is dedicated to transforming the treatment of cancer and chronic viral diseases by targeting critical regulatory pathways.

Vision

Revolution Medicines’ vision is to realise the promise of precision medicine by discovering and developing precision oncology and curative treatments for cancers and other serious diseases.

References

https://in.investing.com/equities/revolution-medicines-inc

https://finance.yahoo.com/quote/RVMD/profile?p=RVMD

https://www.crunchbase.com/organization/revolution-medicines

https://sec.report/CIK/0001628171

https://companiesmarketcap.com/

https://www.revmed.com

Leadership team

Dr. Mark A. Goldsmith Ph.D. (CEO, Pres & Chairman)

Mr. Jack Anders (Chief Financial Officer)

Ms. Margaret A. Horn J.D. (Chief Operating Officer)

Products / Services